CTLA4 Targeted Therapy Plus PD-1 Targeted Therapy Could Benefit Women With Ovarian Cancer

September 19, 2018 12:22 am

An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more